CA2220837A1 - Compositions of interleukin and pyrimidine nucleosides - Google Patents
Compositions of interleukin and pyrimidine nucleosides Download PDFInfo
- Publication number
- CA2220837A1 CA2220837A1 CA002220837A CA2220837A CA2220837A1 CA 2220837 A1 CA2220837 A1 CA 2220837A1 CA 002220837 A CA002220837 A CA 002220837A CA 2220837 A CA2220837 A CA 2220837A CA 2220837 A1 CA2220837 A1 CA 2220837A1
- Authority
- CA
- Canada
- Prior art keywords
- deoxy
- cytidine
- fluoro
- fluorocytidine
- pyrimidine nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin-12 and a pyrimidine nucleoside derivative as well as a hydrate or solvate thereof that is converted into fluorouracil or its derivative, and a pharmaceutically acceptable carrier.
Description
W O96/37214 PCT~EP96/02088 Compositions of interleukin and pvrimidine nucleosides i This invention is concerned with a novel pharmaceutical composition.
More particularly, this invention is concerned with a synergistic antitumor 5 pharmaceutical composition comprising an effective amount of interleukin-12 (IL-12) and a pyrimidine nucleoside, as well as a hydrate or solvate thereof, that is converted into fluorouracil or its derivative, and pharma-ceutically acceptable carrier, a synergistic antitumor pharmaceutical composition for the treatment of various cancer and a method of treating 10 various cancers.
5'-Deoxy-6-fluorouridine (doxifluridine), a pyrimidine nucleoside, is effective in the treatment of various m~lign~nt diseases. Doxifluridine is converted into the active drug 5-FU by pyrimi~ine nucleoside phosphorylases 15 (PyNPase) in vivo, both thymidine and uridine phosphorylases. Therefore, PyNPase is essential for the efficacy of doxifluridine. In fact, tumors with very low levels of this enzyme were refractory to doxifluridine, and PyNPase gene transfection made the tumors more susceptible to this drug. Now, it has surprisingly been found that IL-12 up-regulates PyNPase activity in 20 tumor tissues and consequently enhances the antitumor activity of doxifluridine. IL-12 also enhanced the activity of 5'-deoxy-~-fluoro-N4-(n-pentylcarbonyl)cytidine (capecitabine), which generates doxifluridine and is then converted to 5-FU by PyNPase. In contrast, IL-12 ~nh~n~ed the anti-tumor activity of 6-FU to a lesser extent than the anti-tumor activity of 25 doxifluridine.
It has been reported that some infl~mm~tory cytokines, such as IL-la, TNF-a and IFN-g up-regulate PyNPase activity in tumor cell cultures and consequently enhance the susceptibility to doxifluridine (cf. Eda et al. Cancer 30 Chemother Pharmacol. (1993) 32:333-339, and Jpn. J. Cancer Res. 84, 341-347, March 1993). These cytokines when given parenterally are distributed to various normal tissues through the circulation and cause systemic side effects, such as llu-like syndrome, leukopenia, hypotension, etc. In addition, ~ CA 02220837 1997-11-07 "-.
:' these cytokines distributed to normal tissues as well as tumor tissues would enh~nce PyNPase activity there and make both the normal and tumor tissues more susceptible to doxifluridine. Therefore, these cytokines would enh~nce both the efficacy and toxicity of doxifluridine when given in 5 combin~t,ion IL-12 given parenterally, howevel, induced much higher levels of IFN-g in tumor tissues than in normal tissues. The~efole, IL-12 given parenterally enh~nces PyNPase activity preferentially in tllmor tissues without c~ ing IFN-g-associated systemic side effects.
In a ~lef~lled embodiment of the present invention, the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the ~ following formula (I) or (II), respectively N ~ F H N J~ F
R3 N (I) R3 N (II) YY YY
wherein Rl is hydrogen or an radical which is easily hydrolyzable under physiological conditions; R2 is hydrogen, cyano, fluorine,lower alkyl or lower alkylidene which may be substituted with one or two fluorine atom(s), or ORl; and R3 is lower alkyl, hyllro~y~ethyl, or CH20Rl, as well as a hydrate or solvate thereo~
r.erelled r~lic~l~ which are easily hydrolyzable under physiological conditions of Rl in the above formulae (I) and (II) are R4Co-, R40Co- or R4SCo-wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
Furthermore, ~lefell~d alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 are a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight ch~in of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[in which n is an integer from O to 4, when Y is cyclohexyl, or n is W O96/37214 PCT~EP96/02088 an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl] .
In the above, the term "a saturated, straight or branched hydrocarbon 5 radical ~wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven]" preferably signifies n-propyl, 1-isol.lo~yl-2-methylpropyl, 1,1,2-trimethylpropyl, n-butyl, isobutyl,2-ethylbutyl, 3,3-dimethylbutyl, n-pentyl, isopentyl, neopentyl, 2-propylpentyl,n-hexyl, 2-ethylhexyl, n-heptyl, allyl, 2-buten-1-yl, 3-buten-1-yl, 3-penten-1-yl, 10 4-penten-1-yl, 3-hexen-1-yl, 4-hexen-1-yl, 5 hexen-1-yl, and the like.
The terIn "a radical of the formula (CH2)n-Y lin which n is an integer from O to 4, when Y is a cyclohexyl radical, or n is an integer from 2 to 4, when Y is a lower alkoxy radical having from 1 to 4 carbon atom(s) or a ~5 phenyl radical]" ~.efelably .cigini~es cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 2-methoxyethyl, 2-ethoxyethyl, 2-propoxyethyl, 3-metho~LylJLo~yl, 3-ethu~y~Io~yl, 4-methoxy-butyl, 4-etho~LyL.ulyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, and the like.
Preferred pyrimilline nucleoside for the present invention are:
6'-deoxy-5-lluorouridine, 5-deoxy-5-fluorocytidine, 6'-deoxy-N4-(3 ,5-dimethoxybenzoly)-5-fluorocytidine, 25 5'-deoxy-N4-(3,5-dimethylbenzoly)-5-fluorocytidine, B'-deoxy-N4- [(2,4-dichlorophenyl)acetyl] -5-fluorocytidine, 5'-deoxy-N4-(indol-2-ylacetyl)-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-(3,4,5-trimethylbenzoly)cytidine, 5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 30 5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine, 6'-deoxy-5-fluoro-N4-(neopentyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(1,1,2-trimethylpropoxy)carbonyl]cytidine, 5'-deoxy-N4- [(3 ,3-dimethylbutoxy)carbonyl] -5-fluorocytidine, 35 5'-deoxy-5-fluoro-N4-[(l-isopropyi-2-methylpropoxy)carbonyl]cytidine, 5'-deoxy-N4- [(2-ethylbutyl)oxycarbonyl] -5-fluorocytidine, N4- [(cyclohexylmethoxy)carbonyl] -5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4- [(2-phenylethoxy)carbonyl] cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 2',3'-di-O-acetyl-N4-(butoxycarbonyl)-6'-deoxy-5-fluorocytidine, 2',3'-di-O-benzoyl-N4-(butoxycarbonyl)-6'-deoxy-5-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 5 2',3'-di-O-acetyl-~'-deoxy-6-fluoro-N4-(isopentyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-6'-deoxy-6-fluoro-N4-(hexyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-6'-deoxy-N4- [(2-ethylbutyl)oxycarbonyl] -5-fluorocytidine, 2',3'-di-O-acetyl-N4-[(cyclohexylmethoxy)carbonyl] -6'-deoxy-5-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-[(2-phenylethoxy)carbonyl]cytidine, 10 5'-deoxy-5-fluoro-N4-(isobutoxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(2-propylpentyl)oxycarbonyl]cytidine, 5'-deoxy-N4-[(2-ethylhexyl)oxycarbonyl]-5'-fluorocytidine, 5'-deoxy-5-fluoro-N4-(heptyloxycarbonyl)cytidine, N4-[(2-cyclohexylethoxy)carbonyl]-6'-deoxy-6-fluorocytidine, 15 N4-[(3-cyclohexylpropyl)oxycarbonyl]-5'-deoxy-6-fluorocytidine, N4-(cyclohexyloxycarbonyl)-6'-deoxy-6-fluorocytidine, 5'-deoxy-5-fluoro-N4- [(3-phenylpropyl)oxycarbonyl] cytidine, 5'-deoxy-5-fluoro-N4-[(2-methoxyethoxy)carbonyl]cytidine, N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine 20 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',2'-difluorodeoxycytidine, 5-fluoro-1-tetrahyL Or~ an-1-yluracil, 2'-deoxy-2'-methylidene-5-fluorocytidine, 2'-deoxy-2'-cyano-6-fluorocytidine and 25 as well as hydrate or solvate thereo~
The above mentioned specific compounds are described in U.S. patent Nos. 4,071,680 and 4,966,891, European Patent Nos. 602290-A1, K. Takenuki et al. J. Med. Chem. 31, 1063 (1988), K. Y~magami et al. Cancer Research 61, 30 2319 (1991) and A. Matsuda et al. J. Med. ~hem. 34, 2917 (1991), respectively, and those compounds can be produced according to the method described in the respect*e references or the analogous method thereof.
IL-12 is a heterodimeric cytokine which is produced by antigen 35 presenting cells and serves as a pivotal regulator of T and NK cell function (cf. Stern, A.S. et al. Proc. Natl. Acad. Sci. USA. (1990) 87, 6808-6812 and Kobayashi, M. et al. J. Exp. Med. (1989) 170, 827-845). Biological activities associated with I~12 include its ability to ~?nh~nce the lytic activity of W O 96/37214 PCT~E~96/02088 natural ~illertlymphokine activated killer cells, to induce the secretion of inte.r~:lo.l-g (IFN-g) by both resting and activated T and NK cells, to stimulate the proliferation of activated T and NK cells, to facilitate cytotoxicT lymphocyte responses and to play a critical and unique role in promoting 5 Th-1 type cytokine responses, thereby facilitating cell-mediated immunity (c~ Brunda, M. J. J. Leukocyte Biol. (1994) ~5, 280-288 and Taniguchi, G.
Blood (1994) 84,4008-4027).
IL-12, both human type and murine l,ype, is composed of two dis7l1fide-10 bonded ~ly~op.otein subllnits a~..Jx;..l~tely 35 KDa and 40 KDa in size.
cDNAs encoding each subunit of IL-12 have been cloned and coexpressed in Chinese Hamster Ovary (CHO) cells to yield the secreted, bioactive, hetero~imeric lympho7~ine (Gubler, U. et al. Proc. Nat~. Acad. Sc~. USA.
(1991) 88, 4143-4147 and Sr-h~Rnh~l7t~ D.S. et al. J. Immunol. (1992) 148, 3433-15 3440) A clone of tr~n.qfected CHO cells secreting recomhin~nt IL-12 was selected. Recnmhin~nt IL-12 was purified from the culture supernatant of CHO cells grown in a serum-free medium, by ion P~h~n~e and gel filtration chromatography.
The pharmaceutical compostion of the present invention can be ~r7mini~qtered in any form, for example, tablets, pills, suppositories, capsules, granules, powders, etc. or emulsions. The pharmaceutical composition of the present invention are especially suitable for intramuscular, subcutaneous, or intravenous a~mini.~tration.
Pharmaceutically acceptable carriers and excipients useful in formulating the pharmaceutical composition of the present invention are those commonly used. Pharmaceutically acceptable materials can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral ~(lmini.qtration such as water, gelatine, gum arabic, lactose, starch, m~gnecium stearate, talc, vegetable oils, polyalkylene glycols and petrolel~m jelly. The pharmaceutical composition provided by the present invention can be ~lmini.~tered orally, e.g. in form of tablets, capsules, pills,powders, granules, solutions, syrupsj suspensions or elixirs. The ~lmini.~:tration can also be carried out parenterally, e.g. in form of sterile solutions, suspensions or emulsions; or locally, e.g. in form of solutions, suspensions, salves, powders or aerosols. The pharmaceutical composition can be sterilized and/or can contain further adjuvants such as preserving, W 096137214 P~l/~l~G/02088 -- 6 --st~hili~in~, setting, emulsifying agents, flavor-improving, salts for variation of the osmotic pressure or substances acting as buffers.
The synergistic antitumor pharmaceutical composition of the present 5 invention comprises a single pharmaceutical composition as well as a kit of pharmaceutical compositions each cont~ining the individual active ingredient in a desirable dosage for_. thus, the present invention is also concerned with a kit for the treatment of colorectal cancer, breast cancer, sto~n~h cancer, lung cancer, cervical cancer, bladder cancer and other 10 m~lign~nt diseases which comprises as a first pharmaceutical composition cont~ining an effective amount of IL-12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition cont~ining an effective ~mount of pyrimidine nucleoside derivative, as well as hydrate or solvate thereof and a pharmaceutically acceptable carrier.
Dosage ranges for the pharmaceutical composition of the present invention can easily be determined by one .qkille~l in the art, and depend on the route of ~lmini~ctration~ the age, weight and condition of the patient and the particular disease to be treated. In the case of oral, rectal or parenteral mini~tration for adults, an a~.uxi..~te range from about 0.05 mg/body/day to about 500 mg/body/day of IL-12, and about 50 mg/body/day to about 20,000 mg/body/day of pyrimidine nucleoside generally range from about 1:100 to about 1:400,000. A weight ratio from about 1:1,000 to about 1:10,000 is preferred. Rectal ~mini~tration and intravenous injection are 25 ~ere. . ed routes of ~lmini.ctration of the pharmaceutical composition according to the present invention.
The pharmaceutical compositions of the present invention are useful for the treatment of colorectal cancer, breast cancer, stomach cancer, lung 30 cancer, cervicial cancer, bladder cancer, and other m~lign~nt diseases and the like.
The synergistic antitumor activity of the pharmaceutical composition of the present invention is evident from the tests described hereinafter.
35 (1) Up-regulation of the enzyme for the activation of doxifluridine and 5'-deoxy-5-fluoro-N4-(n-pentyloxycarbonyl)cytidine (capecitabine) by mIL-12.
Six weeks old female C57BL/6 mice or male BALB/c mice were inoculated with A755 m~mm:~y adenocarcinoma (2 x 105 cells) or with Meth A fibrosarcoma (5 x 105 cells), respectively. The mice were given s.c.
mouse IL-12 (mIL-12) at 0.1 mg/mouse or vehicle (0.1 mg/ml of mouse 5 serum albumin dissolved in phosphate-buffered saline) daily for 7 days ~laL l,illg at day 7 and day 8, respectively, after the tumor inoculation. One day thereafter, PyNPase activity in the tumor tissues was measured as described in Eda et al. Cancer Chemother. Pharmacol. 1993; 32:333. Mouse IFN-g (m IFN-g) levels in the tumor tissue were also measured by a 10 commercially available ELISA system (Intertest g, Genzyme).
As Table 1 shows, mIL-12 enh~nred PyNPase activity 11.9 fold in A755 tumors and 2.4 fold in Meth A tumors. This is probably the result of the up-regnl~tion of mIFN-g, which is an up-regulator of PyNPase.
~5 Table 1 Up-regulation of PyNPase and mIFN-g by mIL-12 PyNPase mIFN-g Tumor Model A~mini.qtration Activity Levels (,ug 5-FU/mg/hr)(ng/g tissue) A756 m.qmmZ3ry ca. vehicle 4.4+4.6 a) <2.0 mIL-12 52.3+28.8 *46.8+11.7 *
Meth A fibrosarcoma vehicle 21.4+2.6 <1.1 mIL-12 51.7+9.4 * 6.7+~.1 *
* Statistically .~ignific~nt diLre~eLlce from the vehicle groups (p<0.0~, Student t-test).
35 a) Mean + SD of 6 mice.
2) Selective induction of mIFN-g production by mIL-12 in the tumor tissue.
W O96/37214 PCT~EP96/02088 Six weeks old female C57BL/6 mice were inoculated with A755 m~mm~ry adenocarcinoma (2 x 10~ cells). The mice were given s.c. mIL-12 at 0.1 mgtmouse or vehicle (0.1 mg/ml of mouse serum albumin dissolved in 5 phosphate-burre~ed saline) daily for 7 days starting at day 6 after the tumor inoculation. One day thereafter, mIFN-g levels in the serum and tissue homogenates of tumor and other organs were measured by ELISA system as mentioned above.
-As Table 2 shows, mIL-12 greatly increased mIFN-g levels in tu~nors as compared with those in normal organs. The tumor tissue level of mIFN-g is 3 to 7 fold higher than those of normal tissues so far ~mined and 50 fold higher than those in the circulation. These results suggest that mIL-12 up-regulates PyNPase selectively in the tumor tissue, through the up-regulation ~5 of mIFN-g production by IL-12 selectively in tumor tissues.
Table 2 Selective induction of mIFN-g production by mIL-12 in tumor tissues .
mIFN-g levels (ng/g tissue) a)_ Organs treatment of the mice vehicle mIL-12 tllmor 3.2 + 0.9 32.7 + 9.8 *
serum 0.27 + 0.05 0.66 + 0.22 *
small intestine <2.5 5.3 +4.0 large intestine 2.8 + 0.8 4.3 + 0.5 *
spleen 2.9 + 0.5 9.3 + 1.9 *
liver 2.1 + 1.0 4.2 + 0.6 *
kidney 5.1 + 1.1 7.5 + 1.4 *
thymus b) 6.2 10.3 *; Significantly higher than vehicle group (p<0.05).
a); Mean + SD. n=4 and 5 in vehicle and mIL-12 group, respectively, with an exception of thymus.
b); Values obtained from a comhine~l homogenate of 4 thymuses.
More particularly, this invention is concerned with a synergistic antitumor 5 pharmaceutical composition comprising an effective amount of interleukin-12 (IL-12) and a pyrimidine nucleoside, as well as a hydrate or solvate thereof, that is converted into fluorouracil or its derivative, and pharma-ceutically acceptable carrier, a synergistic antitumor pharmaceutical composition for the treatment of various cancer and a method of treating 10 various cancers.
5'-Deoxy-6-fluorouridine (doxifluridine), a pyrimidine nucleoside, is effective in the treatment of various m~lign~nt diseases. Doxifluridine is converted into the active drug 5-FU by pyrimi~ine nucleoside phosphorylases 15 (PyNPase) in vivo, both thymidine and uridine phosphorylases. Therefore, PyNPase is essential for the efficacy of doxifluridine. In fact, tumors with very low levels of this enzyme were refractory to doxifluridine, and PyNPase gene transfection made the tumors more susceptible to this drug. Now, it has surprisingly been found that IL-12 up-regulates PyNPase activity in 20 tumor tissues and consequently enhances the antitumor activity of doxifluridine. IL-12 also enhanced the activity of 5'-deoxy-~-fluoro-N4-(n-pentylcarbonyl)cytidine (capecitabine), which generates doxifluridine and is then converted to 5-FU by PyNPase. In contrast, IL-12 ~nh~n~ed the anti-tumor activity of 6-FU to a lesser extent than the anti-tumor activity of 25 doxifluridine.
It has been reported that some infl~mm~tory cytokines, such as IL-la, TNF-a and IFN-g up-regulate PyNPase activity in tumor cell cultures and consequently enhance the susceptibility to doxifluridine (cf. Eda et al. Cancer 30 Chemother Pharmacol. (1993) 32:333-339, and Jpn. J. Cancer Res. 84, 341-347, March 1993). These cytokines when given parenterally are distributed to various normal tissues through the circulation and cause systemic side effects, such as llu-like syndrome, leukopenia, hypotension, etc. In addition, ~ CA 02220837 1997-11-07 "-.
:' these cytokines distributed to normal tissues as well as tumor tissues would enh~nce PyNPase activity there and make both the normal and tumor tissues more susceptible to doxifluridine. Therefore, these cytokines would enh~nce both the efficacy and toxicity of doxifluridine when given in 5 combin~t,ion IL-12 given parenterally, howevel, induced much higher levels of IFN-g in tumor tissues than in normal tissues. The~efole, IL-12 given parenterally enh~nces PyNPase activity preferentially in tllmor tissues without c~ ing IFN-g-associated systemic side effects.
In a ~lef~lled embodiment of the present invention, the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the ~ following formula (I) or (II), respectively N ~ F H N J~ F
R3 N (I) R3 N (II) YY YY
wherein Rl is hydrogen or an radical which is easily hydrolyzable under physiological conditions; R2 is hydrogen, cyano, fluorine,lower alkyl or lower alkylidene which may be substituted with one or two fluorine atom(s), or ORl; and R3 is lower alkyl, hyllro~y~ethyl, or CH20Rl, as well as a hydrate or solvate thereo~
r.erelled r~lic~l~ which are easily hydrolyzable under physiological conditions of Rl in the above formulae (I) and (II) are R4Co-, R40Co- or R4SCo-wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
Furthermore, ~lefell~d alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 are a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight ch~in of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[in which n is an integer from O to 4, when Y is cyclohexyl, or n is W O96/37214 PCT~EP96/02088 an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl] .
In the above, the term "a saturated, straight or branched hydrocarbon 5 radical ~wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven]" preferably signifies n-propyl, 1-isol.lo~yl-2-methylpropyl, 1,1,2-trimethylpropyl, n-butyl, isobutyl,2-ethylbutyl, 3,3-dimethylbutyl, n-pentyl, isopentyl, neopentyl, 2-propylpentyl,n-hexyl, 2-ethylhexyl, n-heptyl, allyl, 2-buten-1-yl, 3-buten-1-yl, 3-penten-1-yl, 10 4-penten-1-yl, 3-hexen-1-yl, 4-hexen-1-yl, 5 hexen-1-yl, and the like.
The terIn "a radical of the formula (CH2)n-Y lin which n is an integer from O to 4, when Y is a cyclohexyl radical, or n is an integer from 2 to 4, when Y is a lower alkoxy radical having from 1 to 4 carbon atom(s) or a ~5 phenyl radical]" ~.efelably .cigini~es cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl, 4-cyclohexylbutyl, 2-methoxyethyl, 2-ethoxyethyl, 2-propoxyethyl, 3-metho~LylJLo~yl, 3-ethu~y~Io~yl, 4-methoxy-butyl, 4-etho~LyL.ulyl, phenethyl, 3-phenylpropyl, 4-phenylbutyl, and the like.
Preferred pyrimilline nucleoside for the present invention are:
6'-deoxy-5-lluorouridine, 5-deoxy-5-fluorocytidine, 6'-deoxy-N4-(3 ,5-dimethoxybenzoly)-5-fluorocytidine, 25 5'-deoxy-N4-(3,5-dimethylbenzoly)-5-fluorocytidine, B'-deoxy-N4- [(2,4-dichlorophenyl)acetyl] -5-fluorocytidine, 5'-deoxy-N4-(indol-2-ylacetyl)-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-(3,4,5-trimethylbenzoly)cytidine, 5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 30 5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine, 6'-deoxy-5-fluoro-N4-(neopentyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(1,1,2-trimethylpropoxy)carbonyl]cytidine, 5'-deoxy-N4- [(3 ,3-dimethylbutoxy)carbonyl] -5-fluorocytidine, 35 5'-deoxy-5-fluoro-N4-[(l-isopropyi-2-methylpropoxy)carbonyl]cytidine, 5'-deoxy-N4- [(2-ethylbutyl)oxycarbonyl] -5-fluorocytidine, N4- [(cyclohexylmethoxy)carbonyl] -5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4- [(2-phenylethoxy)carbonyl] cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 2',3'-di-O-acetyl-N4-(butoxycarbonyl)-6'-deoxy-5-fluorocytidine, 2',3'-di-O-benzoyl-N4-(butoxycarbonyl)-6'-deoxy-5-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 5 2',3'-di-O-acetyl-~'-deoxy-6-fluoro-N4-(isopentyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-6'-deoxy-6-fluoro-N4-(hexyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-6'-deoxy-N4- [(2-ethylbutyl)oxycarbonyl] -5-fluorocytidine, 2',3'-di-O-acetyl-N4-[(cyclohexylmethoxy)carbonyl] -6'-deoxy-5-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-[(2-phenylethoxy)carbonyl]cytidine, 10 5'-deoxy-5-fluoro-N4-(isobutoxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(2-propylpentyl)oxycarbonyl]cytidine, 5'-deoxy-N4-[(2-ethylhexyl)oxycarbonyl]-5'-fluorocytidine, 5'-deoxy-5-fluoro-N4-(heptyloxycarbonyl)cytidine, N4-[(2-cyclohexylethoxy)carbonyl]-6'-deoxy-6-fluorocytidine, 15 N4-[(3-cyclohexylpropyl)oxycarbonyl]-5'-deoxy-6-fluorocytidine, N4-(cyclohexyloxycarbonyl)-6'-deoxy-6-fluorocytidine, 5'-deoxy-5-fluoro-N4- [(3-phenylpropyl)oxycarbonyl] cytidine, 5'-deoxy-5-fluoro-N4-[(2-methoxyethoxy)carbonyl]cytidine, N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine 20 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',2'-difluorodeoxycytidine, 5-fluoro-1-tetrahyL Or~ an-1-yluracil, 2'-deoxy-2'-methylidene-5-fluorocytidine, 2'-deoxy-2'-cyano-6-fluorocytidine and 25 as well as hydrate or solvate thereo~
The above mentioned specific compounds are described in U.S. patent Nos. 4,071,680 and 4,966,891, European Patent Nos. 602290-A1, K. Takenuki et al. J. Med. Chem. 31, 1063 (1988), K. Y~magami et al. Cancer Research 61, 30 2319 (1991) and A. Matsuda et al. J. Med. ~hem. 34, 2917 (1991), respectively, and those compounds can be produced according to the method described in the respect*e references or the analogous method thereof.
IL-12 is a heterodimeric cytokine which is produced by antigen 35 presenting cells and serves as a pivotal regulator of T and NK cell function (cf. Stern, A.S. et al. Proc. Natl. Acad. Sci. USA. (1990) 87, 6808-6812 and Kobayashi, M. et al. J. Exp. Med. (1989) 170, 827-845). Biological activities associated with I~12 include its ability to ~?nh~nce the lytic activity of W O 96/37214 PCT~E~96/02088 natural ~illertlymphokine activated killer cells, to induce the secretion of inte.r~:lo.l-g (IFN-g) by both resting and activated T and NK cells, to stimulate the proliferation of activated T and NK cells, to facilitate cytotoxicT lymphocyte responses and to play a critical and unique role in promoting 5 Th-1 type cytokine responses, thereby facilitating cell-mediated immunity (c~ Brunda, M. J. J. Leukocyte Biol. (1994) ~5, 280-288 and Taniguchi, G.
Blood (1994) 84,4008-4027).
IL-12, both human type and murine l,ype, is composed of two dis7l1fide-10 bonded ~ly~op.otein subllnits a~..Jx;..l~tely 35 KDa and 40 KDa in size.
cDNAs encoding each subunit of IL-12 have been cloned and coexpressed in Chinese Hamster Ovary (CHO) cells to yield the secreted, bioactive, hetero~imeric lympho7~ine (Gubler, U. et al. Proc. Nat~. Acad. Sc~. USA.
(1991) 88, 4143-4147 and Sr-h~Rnh~l7t~ D.S. et al. J. Immunol. (1992) 148, 3433-15 3440) A clone of tr~n.qfected CHO cells secreting recomhin~nt IL-12 was selected. Recnmhin~nt IL-12 was purified from the culture supernatant of CHO cells grown in a serum-free medium, by ion P~h~n~e and gel filtration chromatography.
The pharmaceutical compostion of the present invention can be ~r7mini~qtered in any form, for example, tablets, pills, suppositories, capsules, granules, powders, etc. or emulsions. The pharmaceutical composition of the present invention are especially suitable for intramuscular, subcutaneous, or intravenous a~mini.~tration.
Pharmaceutically acceptable carriers and excipients useful in formulating the pharmaceutical composition of the present invention are those commonly used. Pharmaceutically acceptable materials can be an organic or inorganic inert carrier material suitable for enteral, percutaneous or parenteral ~(lmini.qtration such as water, gelatine, gum arabic, lactose, starch, m~gnecium stearate, talc, vegetable oils, polyalkylene glycols and petrolel~m jelly. The pharmaceutical composition provided by the present invention can be ~lmini.~tered orally, e.g. in form of tablets, capsules, pills,powders, granules, solutions, syrupsj suspensions or elixirs. The ~lmini.~:tration can also be carried out parenterally, e.g. in form of sterile solutions, suspensions or emulsions; or locally, e.g. in form of solutions, suspensions, salves, powders or aerosols. The pharmaceutical composition can be sterilized and/or can contain further adjuvants such as preserving, W 096137214 P~l/~l~G/02088 -- 6 --st~hili~in~, setting, emulsifying agents, flavor-improving, salts for variation of the osmotic pressure or substances acting as buffers.
The synergistic antitumor pharmaceutical composition of the present 5 invention comprises a single pharmaceutical composition as well as a kit of pharmaceutical compositions each cont~ining the individual active ingredient in a desirable dosage for_. thus, the present invention is also concerned with a kit for the treatment of colorectal cancer, breast cancer, sto~n~h cancer, lung cancer, cervical cancer, bladder cancer and other 10 m~lign~nt diseases which comprises as a first pharmaceutical composition cont~ining an effective amount of IL-12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition cont~ining an effective ~mount of pyrimidine nucleoside derivative, as well as hydrate or solvate thereof and a pharmaceutically acceptable carrier.
Dosage ranges for the pharmaceutical composition of the present invention can easily be determined by one .qkille~l in the art, and depend on the route of ~lmini~ctration~ the age, weight and condition of the patient and the particular disease to be treated. In the case of oral, rectal or parenteral mini~tration for adults, an a~.uxi..~te range from about 0.05 mg/body/day to about 500 mg/body/day of IL-12, and about 50 mg/body/day to about 20,000 mg/body/day of pyrimidine nucleoside generally range from about 1:100 to about 1:400,000. A weight ratio from about 1:1,000 to about 1:10,000 is preferred. Rectal ~mini~tration and intravenous injection are 25 ~ere. . ed routes of ~lmini.ctration of the pharmaceutical composition according to the present invention.
The pharmaceutical compositions of the present invention are useful for the treatment of colorectal cancer, breast cancer, stomach cancer, lung 30 cancer, cervicial cancer, bladder cancer, and other m~lign~nt diseases and the like.
The synergistic antitumor activity of the pharmaceutical composition of the present invention is evident from the tests described hereinafter.
35 (1) Up-regulation of the enzyme for the activation of doxifluridine and 5'-deoxy-5-fluoro-N4-(n-pentyloxycarbonyl)cytidine (capecitabine) by mIL-12.
Six weeks old female C57BL/6 mice or male BALB/c mice were inoculated with A755 m~mm:~y adenocarcinoma (2 x 105 cells) or with Meth A fibrosarcoma (5 x 105 cells), respectively. The mice were given s.c.
mouse IL-12 (mIL-12) at 0.1 mg/mouse or vehicle (0.1 mg/ml of mouse 5 serum albumin dissolved in phosphate-buffered saline) daily for 7 days ~laL l,illg at day 7 and day 8, respectively, after the tumor inoculation. One day thereafter, PyNPase activity in the tumor tissues was measured as described in Eda et al. Cancer Chemother. Pharmacol. 1993; 32:333. Mouse IFN-g (m IFN-g) levels in the tumor tissue were also measured by a 10 commercially available ELISA system (Intertest g, Genzyme).
As Table 1 shows, mIL-12 enh~nred PyNPase activity 11.9 fold in A755 tumors and 2.4 fold in Meth A tumors. This is probably the result of the up-regnl~tion of mIFN-g, which is an up-regulator of PyNPase.
~5 Table 1 Up-regulation of PyNPase and mIFN-g by mIL-12 PyNPase mIFN-g Tumor Model A~mini.qtration Activity Levels (,ug 5-FU/mg/hr)(ng/g tissue) A756 m.qmmZ3ry ca. vehicle 4.4+4.6 a) <2.0 mIL-12 52.3+28.8 *46.8+11.7 *
Meth A fibrosarcoma vehicle 21.4+2.6 <1.1 mIL-12 51.7+9.4 * 6.7+~.1 *
* Statistically .~ignific~nt diLre~eLlce from the vehicle groups (p<0.0~, Student t-test).
35 a) Mean + SD of 6 mice.
2) Selective induction of mIFN-g production by mIL-12 in the tumor tissue.
W O96/37214 PCT~EP96/02088 Six weeks old female C57BL/6 mice were inoculated with A755 m~mm~ry adenocarcinoma (2 x 10~ cells). The mice were given s.c. mIL-12 at 0.1 mgtmouse or vehicle (0.1 mg/ml of mouse serum albumin dissolved in 5 phosphate-burre~ed saline) daily for 7 days starting at day 6 after the tumor inoculation. One day thereafter, mIFN-g levels in the serum and tissue homogenates of tumor and other organs were measured by ELISA system as mentioned above.
-As Table 2 shows, mIL-12 greatly increased mIFN-g levels in tu~nors as compared with those in normal organs. The tumor tissue level of mIFN-g is 3 to 7 fold higher than those of normal tissues so far ~mined and 50 fold higher than those in the circulation. These results suggest that mIL-12 up-regulates PyNPase selectively in the tumor tissue, through the up-regulation ~5 of mIFN-g production by IL-12 selectively in tumor tissues.
Table 2 Selective induction of mIFN-g production by mIL-12 in tumor tissues .
mIFN-g levels (ng/g tissue) a)_ Organs treatment of the mice vehicle mIL-12 tllmor 3.2 + 0.9 32.7 + 9.8 *
serum 0.27 + 0.05 0.66 + 0.22 *
small intestine <2.5 5.3 +4.0 large intestine 2.8 + 0.8 4.3 + 0.5 *
spleen 2.9 + 0.5 9.3 + 1.9 *
liver 2.1 + 1.0 4.2 + 0.6 *
kidney 5.1 + 1.1 7.5 + 1.4 *
thymus b) 6.2 10.3 *; Significantly higher than vehicle group (p<0.05).
a); Mean + SD. n=4 and 5 in vehicle and mIL-12 group, respectively, with an exception of thymus.
b); Values obtained from a comhine~l homogenate of 4 thymuses.
(3) Antitumor effects of combination of doxifluridine or capecitabine and 30 1) A755 m~n~m~ry adenocarcinoma model A755 (2 x 105 cells) was inoculated s.c. into female C57BL/6 mice. The mice were given mIL-12 (0.03 ,ug/mouse, s.c.), doxifluridine (1.5 mmol/kg, p.o.) and their comhin~tion, daily for 4 weeks, starting from day 9 after the tumor inoculation.
Doxifluridine as a single agent did not show act*ity in tumor ~ ~ ow lh inhibition because A755 tumor has only low levels of PyNPase, whereas W 096/37214 P~li~l~G/02088 mIL-12 was effective (Table 3). mIL-12 in cnmhin~t.ion with doxifluridine was much more effective than mIL-12 alone and regressed the tumor.
The combination effect was more obvious when the survival period 5 was observed (Table 4). Doxifluridine was not effective either in prolongationof the ~u. ~ival period, and IL-12 slightly prolonged the survival period. In contrast, IL-12 and doxifluridine in combination prolonged the survival period much longer than IL-12 alone and some mice were cured (3/5).
Table 3 Antitllmor activity of doxifluridine, mIL-12 and their comhin~tio~ in A755 m~mm~ry adenocarcinoma model.
Treatment Tumor Volume (mm3) % Tllmor Growth on day 25 a) vs. Control vs. mIL-12 alone Control 8969 + 4159 b) 100 doxifluridine 8380 + 2907 93 mIL-12 2399 + 1567 c) 22 100 doxilluridine 216+ 187 c) d) 4 - 16 ~ mIL-12 a) Tumor volllme of 26 days after tumor inoculation was indicated, since thereafter death of mice in the control group were observed because of large tumor burden. The tumor volume on day 9 when the treatment initiated was 513 + 300 mm3.
b) Mean + SD
c) Significantly different from the control group. p < 0.05 d) Significantly different from the mIL-12 group. p < 0.05 Table 4 Survival of mice treated with doxifluridine, mIL-12 and their combin~tion in A755 m::~mm::~ry adenocarcinoma model r TreatmentMedian Survival Increase in Survivors Days (range) Life Span % onDay 153 Control 28 (23 - 42) 0 0/6 doxifluridine29 (22 - 36) 4 0/5 mIL-12 49 (43 55) a) 75 0/5 ~5 doxifluridine + mIL-12>153 (51 - >153) a) b) >446 3/5 a) Significantly dirre~ el~t from the control group. p < 0.05 b) Significantly different from the mIL-12 group. p < 0.05 2) Meth A fibrosarcoma model Meth A fibrosarcoma (5 x 105 cells) was inoculated s.c. into male BALB/c mice. The mice were given doxifluridine (0.5 mmol/kg, p.o.), capecitabine (1.0 mmoVkg, p.o.), 5-fluorouracil (0.075 mmol/kg, p.o.), mIL-12 (0.03 ~Lg/mouse, s.c.), and their combination, daily for 3 weeks, starting from 30 day 8 after the tumor inoculation.
Three fluo~o~y~ ddines or mIL-12 as single agents showed moderate activity in tumor growth inhibition, at the doses employed. mIL-12 in combination with either doxifluridine or capecitabine showed more potent 35 antitumor activity than either drug alone (p < 0.05). On the other hand, mIL-12 and 5-fluorouracil in combination was only slightly more effective than either drug alone (not statistically significant).
W 096/37214 PCT~P96102088 Table 5 Antitumor activity of three fluoropyrimidines (doxifluridine, capecitabine, 5-fluorouracil), mIL-12 and their combination in Meth A
fibrosarcoma model.
Treatment Tumor Volume (mm3) % Tumor Growth on day 29 a) vs. Control vs. mIL-12 Control 10489 + 2054 b) 100 doxifluridine 5170+ 887 c) 48 capecitabine 4941_1397C) 46 ~5 5-fluorouracil 6168+ 530 c) 58 mIL-12 4584_ 1198 c) 42 100 mIL-12 + doxifluridine 19l2-l322cde) 16 39 mIL-12 + capecitabine 2199+ 132gcde) 19 45 mIL-12 + 5-fluorouracil 3603_1786 ce) 32 76 a) Tumor volume of 29 days after tumor inoculation was indicated. The mean tumor volume on day 8 when the treatment initiated was 230 mm3.
b) Mean_ SD
25 c) Significantly different from the control group. p < 0.06 d) Significantly different from the mIL-12 alone group. p < 0.06 e) Significantly different from the corresponding fluoropyrimidine alone group. p < 0.06 The following examples illustrate a pharmaceutical preparation of the present invention and do not limit the scope of the present invention.
Example 1 An injectable solution cont~ining the following ingredients was ~, manufactured in a conventional manner:
S doxifluridine 1000 mg hIL-12 50 ,ug NaCl 41.4 mg NaH2PO4 16.2 mg Na2HPO4 36.7 mg polysorbate 80 4 mg adjust pH 7.0 with 1.2 N HCl or 1 N NaOH
adjust total volume of 20 ml with distilled water for injection ~5 Example 2 An injectable solution each cont~ining the following ingredients was manufactured in a conventional m:inn~r:
capecitabine 100 mg hIL-12 50 ,ug NaCl 718.2 mg NaH2PO4 81 mg Na2HP04 188 mg polysorbate 80 20 mg adjust pH 7.0 with 1.2 N HCl or 1 N NaOH
adjust total volume of 100 ml with distilled water for injection Ex~mple 3 A kit having the following components A and B for treatment of colorectal cancer was manufactured in a conventional manner:
Component A
(granule for oral a~mini.ctration) capecitabine 150 mg hyL o~y~ o~ylmethyl cellulose 29104.5 mg crystalline cellulose 14.7 mg croscarmellose sodium (Ac-Di-Sol)6.0 mg magnesium stearate 1.8 mg coating agent 3.0 mg Total 180 mg Component B
(sterile solution for injection) hIL-12 0.2-20 mg NaCl 116 mg NAH2PO4 62.2 mg Na2HPO4 115.8 mg polysorbate 80 4 mg adjust pH to 7.0 with 1.2 N HCl or lN NaOH
adjust total volume to 20 ml with water for injection
Doxifluridine as a single agent did not show act*ity in tumor ~ ~ ow lh inhibition because A755 tumor has only low levels of PyNPase, whereas W 096/37214 P~li~l~G/02088 mIL-12 was effective (Table 3). mIL-12 in cnmhin~t.ion with doxifluridine was much more effective than mIL-12 alone and regressed the tumor.
The combination effect was more obvious when the survival period 5 was observed (Table 4). Doxifluridine was not effective either in prolongationof the ~u. ~ival period, and IL-12 slightly prolonged the survival period. In contrast, IL-12 and doxifluridine in combination prolonged the survival period much longer than IL-12 alone and some mice were cured (3/5).
Table 3 Antitllmor activity of doxifluridine, mIL-12 and their comhin~tio~ in A755 m~mm~ry adenocarcinoma model.
Treatment Tumor Volume (mm3) % Tllmor Growth on day 25 a) vs. Control vs. mIL-12 alone Control 8969 + 4159 b) 100 doxifluridine 8380 + 2907 93 mIL-12 2399 + 1567 c) 22 100 doxilluridine 216+ 187 c) d) 4 - 16 ~ mIL-12 a) Tumor volllme of 26 days after tumor inoculation was indicated, since thereafter death of mice in the control group were observed because of large tumor burden. The tumor volume on day 9 when the treatment initiated was 513 + 300 mm3.
b) Mean + SD
c) Significantly different from the control group. p < 0.05 d) Significantly different from the mIL-12 group. p < 0.05 Table 4 Survival of mice treated with doxifluridine, mIL-12 and their combin~tion in A755 m::~mm::~ry adenocarcinoma model r TreatmentMedian Survival Increase in Survivors Days (range) Life Span % onDay 153 Control 28 (23 - 42) 0 0/6 doxifluridine29 (22 - 36) 4 0/5 mIL-12 49 (43 55) a) 75 0/5 ~5 doxifluridine + mIL-12>153 (51 - >153) a) b) >446 3/5 a) Significantly dirre~ el~t from the control group. p < 0.05 b) Significantly different from the mIL-12 group. p < 0.05 2) Meth A fibrosarcoma model Meth A fibrosarcoma (5 x 105 cells) was inoculated s.c. into male BALB/c mice. The mice were given doxifluridine (0.5 mmol/kg, p.o.), capecitabine (1.0 mmoVkg, p.o.), 5-fluorouracil (0.075 mmol/kg, p.o.), mIL-12 (0.03 ~Lg/mouse, s.c.), and their combination, daily for 3 weeks, starting from 30 day 8 after the tumor inoculation.
Three fluo~o~y~ ddines or mIL-12 as single agents showed moderate activity in tumor growth inhibition, at the doses employed. mIL-12 in combination with either doxifluridine or capecitabine showed more potent 35 antitumor activity than either drug alone (p < 0.05). On the other hand, mIL-12 and 5-fluorouracil in combination was only slightly more effective than either drug alone (not statistically significant).
W 096/37214 PCT~P96102088 Table 5 Antitumor activity of three fluoropyrimidines (doxifluridine, capecitabine, 5-fluorouracil), mIL-12 and their combination in Meth A
fibrosarcoma model.
Treatment Tumor Volume (mm3) % Tumor Growth on day 29 a) vs. Control vs. mIL-12 Control 10489 + 2054 b) 100 doxifluridine 5170+ 887 c) 48 capecitabine 4941_1397C) 46 ~5 5-fluorouracil 6168+ 530 c) 58 mIL-12 4584_ 1198 c) 42 100 mIL-12 + doxifluridine 19l2-l322cde) 16 39 mIL-12 + capecitabine 2199+ 132gcde) 19 45 mIL-12 + 5-fluorouracil 3603_1786 ce) 32 76 a) Tumor volume of 29 days after tumor inoculation was indicated. The mean tumor volume on day 8 when the treatment initiated was 230 mm3.
b) Mean_ SD
25 c) Significantly different from the control group. p < 0.06 d) Significantly different from the mIL-12 alone group. p < 0.06 e) Significantly different from the corresponding fluoropyrimidine alone group. p < 0.06 The following examples illustrate a pharmaceutical preparation of the present invention and do not limit the scope of the present invention.
Example 1 An injectable solution cont~ining the following ingredients was ~, manufactured in a conventional manner:
S doxifluridine 1000 mg hIL-12 50 ,ug NaCl 41.4 mg NaH2PO4 16.2 mg Na2HPO4 36.7 mg polysorbate 80 4 mg adjust pH 7.0 with 1.2 N HCl or 1 N NaOH
adjust total volume of 20 ml with distilled water for injection ~5 Example 2 An injectable solution each cont~ining the following ingredients was manufactured in a conventional m:inn~r:
capecitabine 100 mg hIL-12 50 ,ug NaCl 718.2 mg NaH2PO4 81 mg Na2HP04 188 mg polysorbate 80 20 mg adjust pH 7.0 with 1.2 N HCl or 1 N NaOH
adjust total volume of 100 ml with distilled water for injection Ex~mple 3 A kit having the following components A and B for treatment of colorectal cancer was manufactured in a conventional manner:
Component A
(granule for oral a~mini.ctration) capecitabine 150 mg hyL o~y~ o~ylmethyl cellulose 29104.5 mg crystalline cellulose 14.7 mg croscarmellose sodium (Ac-Di-Sol)6.0 mg magnesium stearate 1.8 mg coating agent 3.0 mg Total 180 mg Component B
(sterile solution for injection) hIL-12 0.2-20 mg NaCl 116 mg NAH2PO4 62.2 mg Na2HPO4 115.8 mg polysorbate 80 4 mg adjust pH to 7.0 with 1.2 N HCl or lN NaOH
adjust total volume to 20 ml with water for injection
Claims (22)
1. A synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin-12 and a pyrimidine nucleoside derivative represented by the following formula (I) or (II), respectively ( I ) ( II ) wherein R1 is hydrogen or a radical which is easily hydrolyzable under physiologicdl conditions; R2 is hydrogen, cyano, fluorine,lower alkyl or lower alkylidene which may be substituted with one or two fluorine atom(s), or OR1; and R3 is lower alkyl, hydroxymethyl, or CH2OR1, as well as hydrate or solvate thereof, and a pharmaceutically acceptable ~
2. The composition of claim 7, wherein the easily hydrolyzable radical is R4CO-, R4OCO- or R4SCO-, wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
3. The composition of claim 2, wherein the alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 is a saturated, straight or branched hydrocarbon radical twherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[in which n is an integer from 0 to 4, when Y
is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl].
is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl].
4. The composition of claim 1, wherein the pyrimidine nucleoside derivative is selected from the group consisting of:
5'-deoxy-5-fluorouridine, 5-deoxy-5-fluorocytidine, 5'-deoxy-N4-(3,5-dimethoxybenzoly)-5-fluorocytidine, 5'-deoxy-N4-(3,5-dimethylbenzoly)-5-fluorocytidine, 5'-deoxy-N4-[(2,4-dichlorophenyl)acetyl]-5-fluorocytidine, 5'-deoxy-N4-(indol-2-ylacetyl)-5-fluorocytidine, 5'-deoxy-5-fLuoro-N4-(3,4,5-trimethylbenzoly)cytidine, 5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(neopentyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(1,1,2-trimethylpropoxy)carbonyl]cytidine, 5'-deoxy-N4-[(3,3-dimethylbutoxy)carbonyl]-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-[(1-isopropyl-2-methylpropoxy)carbonyl]cytidine, 5'-deoxy-N4-[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine, N4-[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-[(2-phenylethoxy)carbonyl]cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 2',3'-di-O-acetyl-N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine, 2',3'-di-O-benzoyl-N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-5'-deoxy-N4-[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine, 2',3'-di-O-acetyl-N4-[(cyclohexylmethoxy)carbonyl]-5'-deoxy-6-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-[(2-phenylethoxy)carbonyl] cytidine, 5'-deoxy-5-fluoro-N4-(isobutoxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(2-propylpentyl)oxycarbonyl]cytidine, 5'-deoxy-N4-[(2-ethylhexyl)oxycarbonyl]-5'-fluorocytidine, 5'-deoxy-5-fluoro-N4-(heptyloxycarbonyl)cytidine, N4-[(2-cyclohexylethoxy)carbonyl]-5'-deoxy-5-fluorocytidine, N4-[(3-cyclohexylpropyl)oxycarbonyl]-5'-deoxy-5-fluorocytidine, N4-(cyclohexyloxycarbonyl)-5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-[(3-phenylpropyl)oxycarbonyl] cytidine, 5'-deoxy-5-fluoro-N4-[(2-methoxyethoxy)carbonyl] cytidine, N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',2'-difluorodeoxycytidine, 5-fluoro-1-tetrahydrofuran-1-yluracil, 2'-deoxy-2'-methylidene-5-fluorocytidine, 2'-deoxy-2'-cyano-5-fluorocytidine as well as hydrates or solvates thereof.
5'-deoxy-5-fluorouridine, 5-deoxy-5-fluorocytidine, 5'-deoxy-N4-(3,5-dimethoxybenzoly)-5-fluorocytidine, 5'-deoxy-N4-(3,5-dimethylbenzoly)-5-fluorocytidine, 5'-deoxy-N4-[(2,4-dichlorophenyl)acetyl]-5-fluorocytidine, 5'-deoxy-N4-(indol-2-ylacetyl)-5-fluorocytidine, 5'-deoxy-5-fLuoro-N4-(3,4,5-trimethylbenzoly)cytidine, 5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-(neopentyloxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(1,1,2-trimethylpropoxy)carbonyl]cytidine, 5'-deoxy-N4-[(3,3-dimethylbutoxy)carbonyl]-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-[(1-isopropyl-2-methylpropoxy)carbonyl]cytidine, 5'-deoxy-N4-[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine, N4-[(cyclohexylmethoxy)carbonyl]-5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-[(2-phenylethoxy)carbonyl]cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(propoxycarbonyl)cytidine, 2',3'-di-O-acetyl-N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine, 2',3'-di-O-benzoyl-N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(isopentyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-(hexyloxycarbonyl)cytidine, 2',3'-di-O-acetyl-5'-deoxy-N4-[(2-ethylbutyl)oxycarbonyl]-5-fluorocytidine, 2',3'-di-O-acetyl-N4-[(cyclohexylmethoxy)carbonyl]-5'-deoxy-6-fluorocytidine, 2',3'-di-O-acetyl-5'-deoxy-5-fluoro-N4-[(2-phenylethoxy)carbonyl] cytidine, 5'-deoxy-5-fluoro-N4-(isobutoxycarbonyl)cytidine, 5'-deoxy-5-fluoro-N4-[(2-propylpentyl)oxycarbonyl]cytidine, 5'-deoxy-N4-[(2-ethylhexyl)oxycarbonyl]-5'-fluorocytidine, 5'-deoxy-5-fluoro-N4-(heptyloxycarbonyl)cytidine, N4-[(2-cyclohexylethoxy)carbonyl]-5'-deoxy-5-fluorocytidine, N4-[(3-cyclohexylpropyl)oxycarbonyl]-5'-deoxy-5-fluorocytidine, N4-(cyclohexyloxycarbonyl)-5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-[(3-phenylpropyl)oxycarbonyl] cytidine, 5'-deoxy-5-fluoro-N4-[(2-methoxyethoxy)carbonyl] cytidine, N4-(butoxycarbonyl)-5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine, 2',2'-difluorodeoxycytidine, 5-fluoro-1-tetrahydrofuran-1-yluracil, 2'-deoxy-2'-methylidene-5-fluorocytidine, 2'-deoxy-2'-cyano-5-fluorocytidine as well as hydrates or solvates thereof.
5. The composition any one of claims 1 to 4 wherein the weight ratio of interleukin-12 to pyrimidine nucleoside is from about 1:100 to about 1:400,000.
6. The composition any one of claims 1 to 4, wherein the weight ratio of interleukin-12 to pyrimidine nucleoside is from about 1:1,000 to about 1:10,000.
7. A synergistic antitumor pharmaceutical composition for the treatment of colorectal cancer, brest cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases comprising an effective amount of interleukin-12 and a pyrimidine nucleoside as well as a hydrate or solvate thereof, that are converted into fluorouracil or other active metabolite by pyrimidine nucleoside phosphorylase, and a pharmaceutically acceptable carrier.
8. The composition of claim 7, wherein the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the following formula (I) or (II), respectively as defined in claim 2 as well as a hydrate or solvate thereof.
9. The composition of claim 7 wherein the easily hydrolyzable radical is R4CO-, R4OCO- or R4SCO-, wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
10. The composition of claim 9, wherein the alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 is a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y[in which n is an integer from 0 to 4, when Y
is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl].
is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl].
11. The composition of claim 8, wherein the pyrimidine nucleoside derivative is selected from the compounds defined in claim 5.
12. The composition any one of claims 7 to 11, wherein the weight ratio of interleukin-12 to pyrimidine nucleoside is from about 1:100 to about 1:400,000.
13. The composition any one of claims 7 to 11, wherein the weight ratio of interleukin-12 to pyrimidine nucleoside is from about 1:1,000 to about 1:10,000.
14. A method of treating colorectal cancer, brest cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases which comprises administering a synergistic antitumor pharmaceutical composition comprising an effective amount of interleukin-12 and pyrimidine nucleoside or as well as hydrate or solvate thereof, that are converted into fluorouracil or other active metabolite by pyrimidine nucleoside phosphorylase, and a pharmaceutically acceptable carrier.
15. The method of claim 14, wherein the pyrimidine nucleoside is an uridine, cytidine or its derivative represented by the following formula (I) or (II), respectively, as defined in claim 2, as well as a hydrate or solvate thereof.
16. The method of claim 15, wherein the easily hydrolyzable radical is R4CO-, R4OCO- or R4SCO-, wherein R4 is alkyl, cycloalkyl, aralkyl or aryl.
17. The method of claim 16, wherein the alkyl, cycloalkyl, aralkyl or aryl radical represented by R4 is a saturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula (CH2)n-Y [in which n is an integer from 0 to 4, when Y is cyclohexyl, or n is an integer from 2 to 4, when Y is lower alkoxy having 1 to 4 carbon atom(s) or phenyl].
18. The composition of claim 16, wherein the pyrimidine nucleoside derivative is the one selected from the compounds defined in claim 5, as well as a hydrate or solvate thereof.
19. The method any one of claims 14 to 18, wherein the weight ratio of interleukin-12 to pyrimidien nucleoside is from about 1:100 to about 1:400,000.
20. The method any one of claims 14 to 18, wherein the weight ratio of interleukin-12 to pyrimidine nucleoside is from about 1:1,000 to 1:10,000.
21. A kit for the treatment of colorectal cancer, breast cancer, stomach cancer, lung cancer, cervical cancer, bladder cancer and other malignant diseases which comprises as a first pharmaceutical composition containing an effective amount of interleukin-12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition containing an effective amount of a pyrimidine nucleoside derivative as well as a hydrate or solvate thereof and a pharmaceutically acceptable carrier.
22 . The use of interleukin-12 and a pharmaceutically acceptable carrier, and as a second pharmaceutical composition containing an effective amount of a pyrimidine nucleoside derivative as well as a hydrate or solvate thereof for the manufacture of pharmaceutical compositions as claimed in claims 7 or 21.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95108063.9 | 1995-05-26 | ||
| EP95108063 | 1995-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2220837A1 true CA2220837A1 (en) | 1996-11-28 |
Family
ID=8219298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002220837A Abandoned CA2220837A1 (en) | 1995-05-26 | 1996-05-15 | Compositions of interleukin and pyrimidine nucleosides |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0828508A2 (en) |
| JP (1) | JPH10506641A (en) |
| CN (1) | CN1184430A (en) |
| AR (1) | AR005417A1 (en) |
| AU (1) | AU5998296A (en) |
| BR (1) | BR9608779A (en) |
| CA (1) | CA2220837A1 (en) |
| TR (1) | TR199701435T1 (en) |
| WO (1) | WO1996037214A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ330360A (en) * | 1997-06-02 | 1999-03-29 | Hoffmann La Roche | 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents |
| EP0882734B1 (en) * | 1997-06-02 | 2009-08-26 | F. Hoffmann-La Roche Ag | 5'-Deoxy-cytidine derivatives |
-
1996
- 1996-05-15 CA CA002220837A patent/CA2220837A1/en not_active Abandoned
- 1996-05-15 EP EP96917379A patent/EP0828508A2/en not_active Withdrawn
- 1996-05-15 JP JP8535342A patent/JPH10506641A/en active Pending
- 1996-05-15 TR TR97/01435T patent/TR199701435T1/en unknown
- 1996-05-15 WO PCT/EP1996/002088 patent/WO1996037214A2/en not_active Application Discontinuation
- 1996-05-15 CN CN96194016A patent/CN1184430A/en active Pending
- 1996-05-15 AU AU59982/96A patent/AU5998296A/en not_active Abandoned
- 1996-05-15 BR BR9608779A patent/BR9608779A/en not_active Application Discontinuation
- 1996-05-22 AR ARP960102652A patent/AR005417A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR005417A1 (en) | 1999-06-23 |
| TR199701435T1 (en) | 1998-03-21 |
| JPH10506641A (en) | 1998-06-30 |
| BR9608779A (en) | 1999-07-06 |
| MX9708915A (en) | 1998-03-31 |
| CN1184430A (en) | 1998-06-10 |
| EP0828508A2 (en) | 1998-03-18 |
| AU5998296A (en) | 1996-12-11 |
| WO1996037214A2 (en) | 1996-11-28 |
| WO1996037214A3 (en) | 1997-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2590248B2 (en) | Antiviral, antitumor, antimetastasis, immune system enhancing nucleosides and nucleotides | |
| US6344447B2 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| CA2111571C (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| AU2486088A (en) | Antiviral antitumor antimetastatic immune system enhancing nucleosides and nucleotides | |
| WO1994026761A1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| IL112373A (en) | Use of interleukin-12 for the preparation of a pharmaceutical composition for preventing, ameliorating and treating graft-versus-host disease | |
| KR100418483B1 (en) | A composition comprising nonionic surfactants for improvement of hematopoiesis and therapeutic method using the same | |
| JPS6036420A (en) | Effect and method of human tumor necrotic factor and human interferon against human cancer cell | |
| JPH10507441A (en) | Method for treating sepsis or inflammatory disease using oxypurine nucleosides | |
| EP0231819B1 (en) | Pharmaceutical agent for the treatment of myelogenous leukemia | |
| AU732120B2 (en) | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis | |
| EP0488718B1 (en) | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine | |
| Burchenal et al. | Activity of 2-Fluoro-5-methylarabinofuranosyluracil against Mouse Leukemias Sensitive to and Resistant to 1-β-d-Arabinofuranosylcytosine | |
| US6267968B1 (en) | MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same | |
| CA2220837A1 (en) | Compositions of interleukin and pyrimidine nucleosides | |
| US7776838B1 (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| EP0295317A1 (en) | Pharmaceutical composition for the treatment of tumors | |
| MXPA97008915A (en) | Compositions of interleucine and nucleosides of pirimid | |
| CA1316830C (en) | Agent for treating or preventing thrombocytopenia | |
| CA2323791A1 (en) | Purine l-nucleosides, analogs and uses thereof | |
| KR20100131457A (en) | Anti-tumor agent comprising cytidine derivative and carboplatin | |
| CA2322053A1 (en) | Novel nucleosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |